Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
This is an open-label, non-controlled, non-randomized study to investigate the long-lasting
radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluate
response to 177Lu-DOTAEB-TATE in patients with advanced metastatic neuroendocrine tumors.
Different groups with doses of 0.37GBq-0.74GBq (10-20 mCi) and 1.85GBq (50 mCi)of
177Lu-DOTA-EB-TATE,3.7GBq (100 mCi)of 177Lu-DOTA-TATE will be injected intravenously. All
patients will undergo 68Ga-DOTATATE PET/CT scans before and after the treatment.